ArticleActa ophthalmologica2022
Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care.
Article in Acta ophthalmologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 88 citations in OpenAlex.
- Long-term follow-up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half-dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4.Acta ophthalmologica · 2026Trial
- Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Trial
- Neovascular age-related macular degeneration without drusen.Acta ophthalmologica · 2026Article
- Eplerenone for Central Serous Chorioretinopathy: Is There Still Room for This Treatment?Biomedicines · 2026Article
- Review
- Long-term outcomes of titration-guided focal selective retina therapy for chronic central serous chorioretinopathy: retrospective real-world data analysis.BMC ophthalmology · 2026Article
- Ambient light drives verteporfin-induced protein cross-linking during standard laboratory sample processing.PloS one · 2026Article
- Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy.International journal of ophthalmology · 2026Article
- Prevalence of central serous chorioretinopathy in Denmark.Acta ophthalmologica · 2025Article
- [Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy].Die Ophthalmologie · 2025Article
- Global Incidence of Central Serous Chorioretinopathy: A Systematic Review, Meta-analysis, and Forecasting Study.Ophthalmology and therapy · 2025Article
- Efficacy of Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy: A Pilot Study.Journal of personalized medicine · 2025Article
- Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy.Acta pharmaceutica Sinica. B · 2025Article
- Direct navigated focal laser photocoagulation of choroidal neovascularization in central serous chorioretinopathy.Lasers in medical science · 2025Article
- Review
- Subthreshold Laser Titration Database in a Population with Central Serous Chorioretinopathy and Dome-Shaped Macula.Journal of clinical medicine · 2025Article
- Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Dealing with the Verteporfin Shortage: Treatment Options and Outcomes in Patients with Chronic and Non-Resolving Central Serous Chorioretinopathy.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2025Article
- Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma.Advanced nanobiomed research · 2024Article
- Fluorescein angiography patterns and subretinal hyperreflective material predict subthreshold micropulse laser response in chronic central serous chorioretinopathy.BMC ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 17 institutions in 12 countries.
Funding
Abstract
introductionSince July 2021, a worldwide shortage of verteporfin (Visudyne®) occurred: an essential medicine required for photodynamic therapy (PDT). PDT with verteporfin has a broad range of indications in ophthalmology, including chronic central serous chorioretinopathy, polypoidal choroidal vasculopathy and choroidal haemangioma. For these disorders, PDT is either the first-choice treatment or regarded as a major treatment option. MATERIALS AND
methodsA questionnaire was sent to key opinion leaders in the field of medical retina throughout the world, to assess the role of PDT in their country and the effects of the shortage of verteporfin. In addition, information on the application of alternative treatments during shortage of verteporfin was obtained, to further assess the impact of the shortage.
resultsOur questionnaire indicated that the shortage of verteporfin had a major impact on ophthalmic care worldwide and was regarded to be a serious problem by most of our respondents. However, even though there is ample evidence to support the use of PDT in several chorioretinal diseases, we found notable differences in its use in normal patient care throughout the world. Various alternative management strategies were noted during the verteporfin shortage, including lowering the dose of verteporfin per patient, the use of alternative treatment strategies and the use of a centralized system for allocating the remaining ampoules of verteporfin in some countries.
conclusionThe shortage of verteporfin has had a large effect on the care of ophthalmic patients across the world and may have resulted in significant and irreversible vision loss. Mitigation strategies should be developed in consultation with all stakeholders to avoid future medication shortages of verteporfin and other unique ophthalmic medications. These strategies may include mandatory stock keeping, compulsory licensing to an alternative manufacturer or incentivizing the development of competition, for example through novel public-private partnerships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.